3D Tissue Models

View Profile


Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors Review type Summary Keywords File filename File mime type
1. 2012 Gallbladder/Biliary Tract. In: Oncologic Imaging for the Practicing Radiologist, Medical Oncologist and Surgeon Elsevier,
2. 2012 Liver. In: Oncologic Imaging for the Practicing Radiologist, Medical Oncologist and Surgeon. Elsevier
3. 2010 A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer Invest New Drugs
4. 2010 Duration of Diabetes and type of diabetes treatment, increase the risk of hepatocellular carcinoma. Cancer ;116(8):1938-46.
5. 2010 Pretreatment assessment of hepatocellular cancer: expert consensus conference. HPB (Oxford) ;12(5):300-1.
6. 2010 “Epidemiology and Pathogenesis of Hepatocellular Carcinoma” in: Hepatocellular Carcinoma: A Multidisciplinary Approach. Humana Press (2010). Editors: Kelly M. McMasters and Jean-Nicolas Vauthey
7. 2010 “The Future: Combination Systemic Therapy for Hepatocellular Carcinoma” in: Hepatocellular Carcinoma: A Multidisciplinary Approach. Humana Press (2010). Editors: Kelly M. McMasters and Jean-Nicolas Vauthey.
8. 2010 Chapter 15; Hepatobiliary cancers. 2nd edition of the M.D. Anderson Manual of Medical Oncology. McGraw-Hill In Press 2010. Editors: Hagop M. Kantarjian, Charles A. Koller, and Robert A. Wolff.
9. 2009 Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival Surgery;145(4):399-405
10. 2009 Vascular Endothelial Growth Factor (VEGF) in the management of hepatocellular carcinoma. A Review of Literature. Cancer. Cancer
11. 2009 Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States Hepatology ;49(5):1563-70.
12. 2009 Antitumor Activity of Gemcitabine and Oxaliplatin Is Augmented by Thymoquinone in Pancreatic Cancer. Cancer Res 2009; 69
13. 2009 Chemotherapy and Novel Therapies” in: Hepatocellular Carcinoma: A Practical Approach Informa Health Care Publishing Co. Inc., United Kingdom (2009) Editors: Boloni, L; Reddy, K; Al Knawy, B.
14. 2009 Gallbladder and Bile Duct Cancer Chapter 90 the Eighth Edition of Cancer Medicine
15. 2009 Molecular Targets and Therapeutic uses of Kalonji (Thymoquinone)” in “Molecular Targets and Therapeutic uses of Spices: Modern Uses for Ancient Medicine World Scientific Publishing Co., Inc,
16. 2009 A Phase II trial of the combination of bevacizumab and erlotinib in patients with advanced hepatocellular carcinoma J Clin Oncol ;27(6):843-50.
17. 2008 Utility of animal models in pancreatic cancer research. Pancreatic Cancer, Lowy, Leach and Philip (Eds) Chapter 34. Springer, New York, NY, USA pp 577-599,
18. 2008 Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study J Cancer ;123(8):1883-91.
19. 2008 The association of family history of liver cancer with hepatocellular carcinoma: USA case-control study J Hepatol
20. 2007 Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer Cancer Res 67:7782-8
21. 2007 Identification of prostate cancer mRNA markers by averaged differential expression and their detection in biopsies, blood, and urine Proc Natl Acad Sci U S A 104:2343-8
22. 2006 Vaccines in Medical Oncology”, “Biological Response Modifiers in Cancer Therapy”, and “Cancer Gene Therapy” in: Contemporary Perspectives on Clinical Pharmacotherapeutics Elsevier Publishing Co. Inc. Editors: Kohli, K
23. 2005 Sensitive detection of Human Papilloma virus in cervical, head/neck and schistosomiasis-associated bladder. Proc Natl Acad Sci USA 102:7683-8
24. Answer questions and earn CME/CNE Chronic hepatitis C virus (HCV) infection affects millions of people worldwide and is associated with cancer. Pubmed Answer questions and earn CME/CNE Chronic hepatitis C virus (HCV) infection affects millions of people worldwide and is associated with cancer. Direct-acting antivirals (DAAs) have changed HCV treatment paradigms, but little is known about the management of HCV infection in patients with cancer. The substantial burden of HCV infection and the inconclusive evidence regarding its detection and management in patients with cancer prompted the authors to review the literature and formulate recommendations. Patients for whom HCV screening is recommended included all patients with hematologic malignancies, hematopoietic cell transplantation candidates, and patients with liver cancer. There is a lack of consensus-based recommendations for the identification of HCV-infected patients with other types of cancer, but physicians may at least consider screening patients who belong to groups at heightened risk of HCV infection, including those born during 1945 through 1965 and those at high risk for infection. Patients with evidence of HCV infection should be assessed by an expert to evaluate liver disease severity, comorbidities associated with HCV infection, and treatment opportunities. DAA therapy should be tailored on the basis of patient prognosis, type of cancer, cancer treatment plan, and hepatic and virologic parameters. HCV-infected patients with cancer who have cirrhosis (or even advanced fibrosis) and those at risk for liver disease progression, especially patients with HCV-associated comorbidities, should have ongoing follow-up, regardless of whether there is a sustained virologic response, to ensure timely detection and treatment of hepatocellular carcinoma. HCV infection and its treatment should not be considered contraindications to cancer treatment and should not delay the initiation of an urgent cancer therapy. CA Cancer J Clin 2017. © 2017 American Cancer Society. CA Cancer J Clin 2017;67:411-431. © 2017 American Cancer Society. cancer; direct-acting antiviral; hepatitis C virus (HCV); hepatocellular carcinoma; non-Hodgkin lymphoma; primary liver cancer
25. Predicting outcomes in patients with hepatocellular carcinoma (HCC) who undergo locoregional therapies remains a substantial clinical challenge. Pubmed Predicting outcomes in patients with hepatocellular carcinoma (HCC) who undergo locoregional therapies remains a substantial clinical challenge. The purpose of this study was to investigate pre-procedure diffusion weighted magnetic resonance imaging (DW-MRI) as an imaging biomarker for tumoral response to therapy for patients with HCC undergoing drug eluting embolic (DEE) chemoembolization and radioembolization. A retrospective review of HCC patients who underwent DEE chemoembolization or radioembolization was performed. Of the 58 patients who comprised the study population, 32 underwent DEE chemoembolization and 26 underwent radioembolization. There was no significant difference in median apparent diffusion coefficient (ADC) values across the two treatment groups (1.01 × 10-3 mm²/s, P = 0.25). The immediate objective response (OR) rate was 71% (40/56). Tumors with high ADC values were found to have a higher probability of OR within 90 days (odds ratio 4.4, P = 0.03). Moreover, index lesion specific progression free survival (PFS) was greater for high ADC tumors, independent of conventional predictors of treatment response (hazard ratio 0.44, P = 0.01). Low ADC was associated with poorer PFS (P = 0.02). Pre-procedure ADC < 1.01 × 10-3 mm²/s is an independent predictor of poorer immediate OR and index lesion specific PFS in patients with HCC undergoing DEE chemoembolization or radioembolization. chemoembolization; diffusion weighted imaging; hepatocellular carcinoma


About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.